and ClfB are characterized by the presence of a region known as region R, which consists of repeating serine and aspartic acid dipeptides (SD repeats). Region R connects the cell wall-spanning domain to the unique ligand-binding region (region A). ClfA and ClfB are members of a larger family of S. aureus proteins known as the serineaspartate repeat (Sdr) protein family (Josefsson et al., 1998a) . The Sdr proteins are predicted to have a similar structural organization to ClfA and ClfB. In addition, they contain two (SdrC), three (SdrE) and five (SdrD) B repeats of 110-113 residues, which separate the A region from the R domain.
A previous study suggested that protein A (Spa) was required for S. aureus-induced platelet aggregation (Hawiger et al., 1979) . Protein A is a surface-displayed, cell wall-associated protein that contains varying numbers of repeat domains (Sjödahl, 1977; Moks et al., 1986) . It is primarily known for its ability to bind to the Fc region of mammalian IgG. However, recently, Spa was shown to bind to von Willebrand factor (Hartleib et al., 2000) , which is recognized by the platelet glycoprotein GPIb, and to the complement receptor gC1qR/p33 (Nguyen et al., 2000) , which is also on the platelet surface. Thus, there are several possible mechanisms by which Spa-expressing S. aureus cells may interact with platelets.
One of the problems encountered in comparing the ability of different S. aureus strains to interact with platelets or indeed to other host components is the fact that they often express a different profile of surface proteins (Peacock et al., 2000; Rice et al., 2001) , and the level of expression can also vary from strain to strain (McAleese et al., 2001) . Therefore, when comparing strains to identify novel interactions, it is essential to use site-specific isogenic mutants. A report claiming that the failure of the protein A-deficient S. aureus strain Wood 46 to bind platelets compared with the positive interaction by the protein A-expressing S. aureus strain Cowan I, implying that protein A was responsible, did not account for the possibility that these strains most probably differed in the expression of other surface proteins (Nguyen et al., 2000) .
To identify the S. aureus surface proteins involved in the activation of human platelets, we tested the ability of specific mutants of S. aureus strain Newman that were defective in the expression of various cell wall-associated proteins to activate platelet aggregation. This approach was complemented by the expression of S. aureus surface proteins individually in the non-aggregating Gram-positive bacterium Lactococcus lactis.
Results

Expression of surface proteins by S. aureus and L. lactis
Staphylococcus aureus mutants defective in the expres-sion of specific surface proteins were prepared by sitespecific mutagenesis, and L. lactis strains that expressed ClfA, ClfB, SdrC, SdrD, SdrE, protein A (Spa) and Map were constructed using the expression vector pKS80. The expression of these proteins was studied by Western immunoblotting using specific antibodies, except for protein A, which was recognized by its ability to bind IgG in a non-immune reaction (Fig. 1) .
When tested with anti-ClfA antibodies, S. aureus Newman showed a single immunoreactive band of 170 kDa, which was missing in the clfA mutant, whereas L. lactis (pKS80:clfA) expressed two immunoreactive bands of 170 kDa and 130 kDa ( Fig. 1A) . Both Newman and L. lactis (pKS80:clfB), but not Newman clfB, expressed two immunoreactive bands of 150 kDa and 120 kDa when reacted with anti-ClfB antibodies (Fig. 1B) . The 170 kDa ClfA molecule and the 150 kDa ClfB molecule are the fulllength intact forms of the proteins, whereas the 130 kDa ClfA and the 120 kDa ClfB moieties have been cleaved at the motif SLAAVA (ClfA) or SLAVA (ClfB) by the staphylococcal metalloprotease (McAleese et al., 2001; unpublished data) . The ClfA truncate is functional, whereas the ClfB truncate does not bind fibrinogen (O'Connell et al., 1998; McAleese et al., 2001) .
A protein of 180 kDa reacted with anti-SdrE antibodies in Newman and L. lactis (pKS80:sdrE), but not in Newman sdrE (Fig. 1C ). N-terminal sequencing of the L. lactis-expressed 180 kDa protein revealed the sequence AENTST, which corresponds to that predicted to be at the N-terminus after cleavage of the signal peptide. We conclude that the full-length form of SdrE is anchored to the surface of L. lactis.
Staphylococcus aureus Newman wild-type cells and L. lactis (pKS80:spa) cells both expressed an IgG-binding protein of 55 kDa. This protein was not detected in either the L. lactis host strain or a Newman spa mutant. L. lactis (pKS80:sdrC) expressed a 160 kDa protein that reacted with anti-SdrC antibodies, L. lactis (pKS80:sdrD) expressed a 205 kDa protein that reacted with anti-SdrD antibodies, and L. lactis (pKS80:map) expressed a 70 kDa protein that reacted with anti-map antibodies (data not shown).
Comparative analysis by flow cytometry of S. aureus Newman and L. lactis cells expressing either ClfA or protein A showed that L. lactis cells expressed similar levels of protein on their surface compared with S. aureus. The relative fluorescence of ClfA expressed on the surface of S. aureus was 179 ± 70, whereas the relative fluorescence of ClfA expressed on the surface of L. lactis was 169 ± 56 (P > 0.05). Similarly, the relative fluorescence of protein A expressed on the surface of S. aureus was 29 ± 16, whereas the relative fluorescence given by the protein A molecules expressed on the surface of L. lactis was 27 ± 11 (P > 0.05). These data show that the heterologous proteins are expressed on the surface of L. lactis at levels similar to S. aureus. Furthermore, the ability of protein A to recognize and bind non-immune IgG indicates that this protein is functional when expressed on the surface of L. lactis. Functional analysis of S. aureus protein expressed in L. lactis
In order to determine whether S. aureus cell wallassociated proteins were expressed in a functional form on the surface of L. lactis, the ClfA-and ClfB-expressing strains were tested for their ability to adhere to immobilized fibrinogen. Both strains adhered in a dosedependent and saturable fashion (Fig. 2 ) similar to the ClfA-or ClfB-dependent adhesion of S. aureus Newman (ClfA + ClfB -) and Newman (ClfA -ClfB + ). L. lactis cells expressing either ClfA or ClfB adhered to fibrinogen with a slightly higher affinity than the S. aureus-expressed protein (Fig. 2 ). It should be noted that ClfB-mediated fibrinogen binding by S. aureus (Newman) can only be studied with cells from the exponential phase of growth (Ní Eidhin et al., 1998; McAleese et al., 2001) . In contrast, ClfA and SdrE were expressed on cells from both exponential and stationary phases. These data showed that both ClfA and ClfB were expressed in a fully functional form on the surface of L. lactis.
Platelet aggregation
The ability of S. aureus strain Newman cells to induce platelet aggregation in PRP was tested. S. aureus Newman wild-type cells, which were grown to exponential phase, induced platelet aggregation with a lag time of In each blot, proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes and probed with specific rabbit antibodies to ClfA (A), antibodies to ClfB (B) and antibodies to SdrE (C) followed by protein A peroxidase. In (D), membranes were probed with non-immune rabbit IgG followed by peroxidase-conjugated goat anti-rabbit IgG. Newman wild-type cells, which had been grown to stationary phase, induced platelet aggregation with a lag time of 1.5 ± 0.1 min (n = 3), also with a monophasic response. This is in contrast to arachidonic acid-induced platelet aggregation, which has a lag time of 0.12 ± 0.01 min (n = 3) in PRP. These results showed that S. aureus strain Newman could activate platelet aggregation and that this phenomenon was dependent on the growth phase of the bacterium.
Effects of platelet inhibitors
A previous report suggested that S. aureus-induced platelet aggregation was not dependent on the platelet receptor GPIIb/IIIa, so we decided to investigate this. Human platelets (PRP) were incubated with the GPIIb/IIIa antibody inhibitors abciximab, eptifibatide, tirofiban or the GPIIb/IIIa peptide inhibitor, RGDS (Arg-Gly-Asp-Ser). Aggregation experiments were then performed using either S. aureus strain Newman or adenosine diphosphate (ADP) as agonists. The results showed that each of these inhibitors prevented platelet aggregation by both S. aureus cells and ADP ( Fig. 3 ). S. aureus strain Newman-induced platelet aggregation was also completely inhibited by 1 mM aspirin (a cyclooxygenase inhibitor; 47 ± 1% control and 0% with aspirin, n = 4) and by 1 mM prostaglandin E1 (PGE 1 ; 48 ± 9% control and 1 ± 0.3% with PGE 1 , n = 3). Although 10 U ml -1 apyrase (ADPase) totally inhibited ADP-induced aggregation, it had no effect on S. aureus Newman-induced aggregation (43 ± 5% control and 36 ± 4% with apyrase, n = 3). (Some agonists depend on ADP secretion during activation.) These results indicate that S. aureus-induced platelet aggregation is indeed true aggregation that occurs in a GPIIb/IIIa-dependent fashion, but that it is not secretion dependent. It should be noted that the comparison between S. aureus-induced platelet aggregation and ADP-induced platelet aggregation is expressed here as percentage aggregation rather than as lag time. When comparing bacterial variants (see below), data are expressed as the lag time to aggregation. Fig. 2 . Adherence of L. lactis and S. aureus cells expressing ClfA and ClfB to immobilized fibrinogen. ELISA plates (96-well) were coated with different concentrations of fibrinogen ranging from 0.3 to 10 mg ml -1 . Adherence of L. lactis MG1363 wild type (closed diamonds), L. lactis (pKS80:clfA; closed squares), L. lactis (pKS80:clfB; closed circles) and S. aureus Newman ClfA -(open squares), Newman ClfB -(open circles) and Newman ClfA -ClfB -(crosses) to immobilized fibrinogen was tested. Adherent cells were stained with crystal violet and measured in an ELISA plate reader at 570 nm. Fig. 3 . Inhibition of S. aureus-induced platelet aggregation by GPIIb/IIIa inhibitors. Plateletrich plasma was pretreated with abciximab (10 mg ml -1 ), eptifibatide (1 mM), RGDS (500 mM) or no inhibitor (control) for 10 min before the addition of the agonists (ADP, 20 mM, black columns; or S. aureus Newman cells from exponential phase, OD 1.6, blank columns). * indicates P < 0.01. Results are expressed as percentage aggregation.
Ability of S. aureus mutants to induce human platelet aggregation
In order to identify factors responsible for the activation of platelet aggregation by S. aureus Newman, a series of mutants defective in surface factors was tested. Strains deficient in the clumping factors ClfA or ClfB, protein A, the elastin-binding protein EbpS, the fibronectin-binding proteins FnBPA and FnBPB, the SD repeat proteins SdrC or SdrD, the major histocompatibility complex (MHC) class II analogous protein, coagulase and capsular polysaccharide 5 induced platelet aggregation with lag times similar to that of the wild-type strain (5 ± 2 min). Exponential phase cells were used because work in our laboratory and elsewhere has demonstrated that S. aureus Newman proteins ClfB, FnBPA and FnBPB are expressed predominantly in that phase (Greene et al., 1995; Saravia-Otten et al., 1997; McAleese et al., 2001) . However, it should be noted that other proteins are expressed on the surface of S. aureus cells throughout the growth cycle. We compared, by flow cytometry, the level of ClfA on the surface of Newman spa cells from exponential phase and from stationary phase, in which the mean fluorescence was 2283 ± 66 and 426 ± 122 respectively (P < 0.01). The approximately fivefold higher ClfA on stationary phase cells could explain the faster activation time of cells from this phase of growth described above.
Role of ClfA and ClfB in S. aureus-induced platelet aggregation
As ClfA is known to interact directly with platelets and fibrinogen binding plays a crucial role in platelet aggregation, it was decided to investigate the possible roles for the fibrinogen-binding S. aureus proteins ClfA and ClfB in this process. S. aureus strain Newman wild type and Newman clfA, clfB and clfA clfB mutants were grown to exponential phase and tested for their ability to induce platelet aggregation. In gel-filtered platelets (GFPs) supplemented with fibrinogen, both clfA and clfB single mutants induced platelet aggregation with lag times similar to that of the wild-type strain (Fig. 4) . Supplementing the GFPs with fibrinogen was essential, as S. aureus wild-type cells failed to induce aggregation of GFPs in the absence of fibrinogen (47 ± 4% with fibrinogen and 0% without). In contrast, the clfA clfB double mutant failed to induce aggregation. However, when the experiment was performed with PRP, platelet aggregation was detected with both clfA and clfB single mutants and with the clfA clfB double mutant (Fig. 4) . The lag times observed with each of the mutant strains in PRP were comparable with that of the wild-type strain. These results indicated that both ClfA and ClfB stimulated S. aureus-induced platelet aggregation in a fibrinogendependent fashion and that at least one further fibrinogen-independent mechanism was identified. The third mechanism was capable of stimulating platelet aggregation independently of ClfA and ClfB only in PRP. Thus, there is considerable functional redundancy in factors used by S. aureus Newman to activate platelets.
Effect of S. aureus proteins expressed in L. lactis on human platelet aggregation
As the mechanism by which S. aureus activated platelet aggregation appeared to be multifactorial and compensatory, an alternative approach to identifying the protein(s) involved in the process was used. Candidate S. aureus surface proteins ClfA, ClfB, SdrC, SdrD, SdrE, protein A, EbpS and Map were expressed in the non-aggregating surrogate Gram-positive host L. lactis. L. lactis cells expressing SdrC, SdrD, protein A, Map or EbpS did not induce platelet aggregation in PRP, whereas L. lactis expressing ClfA, ClfB or SdrE did induce platelet aggregation ( Fig. 5 ). L. lactis cells expressing ClfA induced platelet aggregation with the shortest lag times (1.5 ± 0.5 min, n = 3). In contrast, SdrE-expressing L. lactis cells activated platelet aggregation with relatively long lag times (13.5 ± 3.5 min, n = 8), whereas ClfB-expressing L. . Activation of platelet aggregation by S. aureus Newman in platelet-rich plasma and with gel-filtered platelets. The ability of Newman wild-type and Newman ClfA -, Newman ClfBand Newman ClfA -ClfBmutant cells, grown to exponential phase, to activate platelet aggregation in PRP (black columns) or GFP (blank columns) was tested. ** indicates that no aggregation occurred after 30 min incubation. Results are presented as a comparison between the time taken to aggregation for each strain. The degree of aggregation observed (percentage aggregation) was comparable for each of the strains in which aggregation occurred.
lactis cells activated platelets with a lag time of 7 ± 2 min (n = 3).
The ability of L. lactis cells expressing ClfA, ClfB or SdrE to activate platelet aggregation in GFPs was also tested. L. lactis cells expressing ClfA or ClfB activated platelet aggregation in GFPs with similar lag times to that of PRP, whereas no aggregation in GFPs was observed for L. lactis cells expressing SdrE (data not shown). In addition, the recombinant A region of SdrE (rSdrEA) inhibited SdrE-expressing L. lactis-mediated platelet aggregation in a dose-dependent manner (data not shown) after preincubation of the protein with the platelets. This indicates that activation by SdrE results from a specific receptor-ligand interaction.
These data confirmed observations with S. aureus mutants that ClfA and ClfB are capable of activating platelet aggregation and show that they can do so independently of other S. aureus surface molecules. A third mechanism involving the SD repeat-containing protein SdrE was also identified.
The role of ClfA, SdrE and protein A in the activation of platelet aggregation identified using S. aureus mutants In order to show that ClfA and SdrE could promote the activation of platelet aggregation when expressed on the surface of S. aureus cells and to investigate the role of protein A further, experiments were performed with mutants lacking different combinations of surface proteins. It should be pointed out that cells from the stationary phase of growth were used where ClfA, SdrE and Spa are known to be expressed, but where ClfB is lacking (McAleese et al., 2001) .
Cells of Newman wild type, Newman sdrE, Newman spa, Newman clfA, Newman clfA spa, Newman clfA sdrE and Newman clfA spa sdrE from the stationary phase of growth (which were phenotypically ClfB -) were tested. Newman wild-type, Newman spa and Newman sdrE cells all induced platelet aggregation with very similar lag times (1.8 ± 0.1 min, n = 3). In contrast, a significant delay in lag time to aggregation was observed with the Newman clfA mutant cells (9 ± 1 min, n = 3), suggesting that ClfA is the dominant activating factor in the absence of ClfB. A further increase in lag time was observed with the Newman clfA spa mutant cells (21 ± 9 min, n = 3) and with Newman clfA sdrE mutant cells (17.8 ± 3.5 min, n = 3), whereas the Newman clfA spa sdrE mutant did not promote platelet aggregation (Fig. 6) . Aggregations by the mutants were inhibited by GPIIb/IIIa antagonists (data not shown), Fig. 5 . Activation of platelet aggregation by L. lactis cells expressing S. aureus surface proteins. L. lactis (MG1363) and L. lactis MG1363 cells expressing SdrC, SdrD, Spa, EbpS, Map, ClfA, ClfB or SdrE were tested for their ability to activate platelet aggregation. ** indicates that aggregation did not occur after 30 min incubation. Results are expressed as a comparison of the time taken to aggregation for each strain. S. aureus Newman wild-type cells (grown to exponential phase) and L. lactis cells expressing ClfA, ClfB or SdrE all induced a similar degree (percentage) of aggregation. Fig. 6 . Activation of platelet aggregation by S. aureus strain Newman clfA, spa and sdrE mutants. S. aureus strain Newman wild type and S. aureus Newman spa (DU5971), Newman sdrC sdrD sdrE (DU5973), Newman clfA (DU5876), Newman clfA spa (DU5976) and Newman sdrC sdrD sdrE spa clfA (DU5975) were grown to stationary phase and tested for their ability to activate platelet aggregation in PRP. ** indicates that aggregation did not occur after 30 min incubation. Results are expressed as a comparison of the time taken to aggregation for each strain.
indicating that they were true aggregation events and not agglutination. However, the aggregation profile of Newman clfA sdrE with PRP from two of the three donors presented as a slow drift rather than a normal aggregation trace.
These data showed that both ClfA and SdrE could stimulate platelet aggregation when expressed on the surface of S. aureus strain Newman, thus confirming the results obtained with L. lactis. Protein A was not capable of activating platelet aggregation independently, but we showed that it does play a role when expressed on the surface of S. aureus cells.
Discussion
In this paper, we have exploited our ability to manipulate genetically the expression of the surface proteins of S. aureus strain Newman in order to dissect the multifactorial process by which S. aureus cells induce platelet aggregation. S. aureus mutants expressing different combinations of surface proteins were constructed. This approach was complemented by the expression of each protein separately on the surface of the surrogate Grampositive bacterium L. lactis.
We validated this strategy by showing that each of the S. aureus surface proteins implicated in the process of platelet activation was expressed in the full-length, functional form on the surface of L. lactis. Each protein was analysed by Western immunoblotting after enzymatic release from the cell wall, and the level of expression of ClfA and protein A on S. aureus and L. lactis was compared by flow cytometry.
Analysis of the function of staphylococcal surface proteins in the Clf-Sdr family is confounded by the fact that they are cleaved by a metalloprotease. In the case of ClfB, cleavage destroys the ligand-binding activity of the protein and is partly responsible for the loss of ClfB-promoted binding by cells in the stationary phase of growth (McAleese et al., 2001) . In contrast, the population of ClfA molecules on S. aureus cells from the stationary phase is only partially degraded and, in any case, the cleaved form of ClfA still binds fibrinogen (O'Connell et al., 1998) . When staphylococcal Clf-Sdr proteins were expressed on the surface of L. lactis and analysed by Western immunoblotting, we observed that the proteins were degraded in a time-dependent fashion during mutanolysin/lysozyme solubilization of cell wall peptidoglycan, presumably as a result of exposure to membraneassociated proteases (data not shown). It is our contention that the majority of molecules of each protein are intact and fully functional on the surface of L. lactis cells. Indeed, the ClfA and ClfB proteins expressed on the surface of L. lactis promoted more avid adherence to fibrinogen than S. aureus Newman, despite being expressed at similar levels. This may result from there being more full-length intact molecules on the surface of L. lactis compared with S. aureus. Alternatively, it is possible that the fibrinogenbinding capacity of both ClfA and ClfB is masked slightly by other surface proteins that are expressed by S. aureus.
Platelet aggregation that followed the addition of S. aureus cells to PRP or GFPs was monophasic and inhibited by several GPIIb/IIIa antagonists, by the cyclooxygenase inhibitor aspirin and by prostaglandin E 1 , which elevates intracellular cAMP, thereby inhibiting platelet aggregation. This indicates that the response was true aggregation, that was dependent on cyclooxygenase followed by activation of GPIIb/IIIa and fibrinogen binding. Activation was not dependent on ADP secretion because it occurred normally in the presence of apyrase (ADPase). Similar results were obtained with endocarditis isolates (data not shown), indicating that this is a general property of S. aureus.
In contrast, a previous study indicated that aggregation of rabbit platelets by S. aureus strains Newman and Lafferty was biphasic and was not inhibited by the RGDS peptide, an antagonist of GPIIb/IIIa . The action of GPIIb/IIIa antagonists including RGDS is highly species specific, and most have very little activity against platelets from rabbits or rodents (Cox et al., 1992) . The aggregation response of rabbit platelets caused by Newman clfA was altered, in that there was no second phase in the biphasic response characteristic of the wild type . However, in contrast to our studies, the lag time to activation with the Newman clfA mutant was not prolonged. This suggests that a factor other than ClfA had a more dominant role in promoting the aggregation of rabbit platelets, whereas ClfA is the dominant factor for the activation of human platelets.
With gel-filtered human platelets, we have shown that S. aureus Newman cells expressing either ClfA or ClfB induced aggregation whereas the Newman clfA clfB double mutant did not. However, in contrast, the Newman clfA clfB mutant did support aggregation in PRP. These results suggested that an additional mechanism, capable of inducing aggregation in plasma, must exist.
Clearly, S. aureus-mediated platelet aggregation is a complex process that involves at least three different surface proteins. Therefore, using isogenic mutants to identify the proteins is difficult. Hence, in order to identify the ClfA-and ClfB-independent mechanism(s), an alternative approach was adopted. The genes for candidate proteins were cloned and expressed in the Gram-positive surrogate host L. lactis allowing the expression of individual proteins from S. aureus. L. lactis does not induce platelet aggregation and therefore provides a suitable host for studying the proaggregatory ability of individual S. aureus proteins. Our results showed that ClfA, ClfB and SdrE could independently induce platelet aggregation in PRP and thus supported data obtained with S. aureus Newman clfA and clfB mutants. In addition, a mechanism involving SdrE was identified.
In contrast, although protein A was shown to be intact and functional on the surface of L. lactis (pKS80:spa), these cells could not promote platelet activation. However, Spa did appear to be capable of contributing to the activation of platelet aggregation when expressed on the surface of S. aureus. Both Newman clfA spa and Newman clfA sdrE mutants activated platelets, whereas a Newman clfA spa sdrE mutant did not. In S. aureus, it is possible that protein A acts in conjunction with a surface protein other than ClfA, ClfB or SdrE to trigger aggregation and that this is the reason why L. lactis cells expressing protein A do not activate One possible explanation for the long lag time to aggregation for Newman clfA sdrE could be that protein A might act by binding antibody and allowing complement formation. Streptococcus sanguis induces platelet aggregation by interacting with a platelet complement receptor and the Fc receptor (Ford et al., 1997) . This aggregation has a long lag time of 18-20 min. Another possibility is that the interaction between protein A and SdrE with their platelet receptors is relatively weak and requires a longer period of time to trigger the aggregation process. We propose that the interaction between ClfA and its receptor is strong and thus triggers a rapid reaction, independently of other molecules. In fact, the level of ClfA present on the surface of S. aureus cells correlates directly with the length of lag time to aggregation. Stationary phase S. aureus Newman cells have about five times more ClfA on their surface, and their lag time is five times faster than exponential phase bacteria.
Plasma proteins play an important role in S. aureusinduced platelet aggregation. The SdrE platelet interaction did not occur with gel-filtered platelets but required the presence of plasma. Neither the S. aureus Newman clfA clfB double mutant nor the L. lactis SdrE-expressing cells induced platelet aggregation in GFPs. ClfA might interact with resting platelets by binding fibrinogen, which can then bind to GPIIb/IIIa (McDevitt et al., 1994) . A similar interaction might also occur between ClfB and the platelet. However, ClfA has also been shown to interact directly with a platelet membrane protein (Siboo et al., 2001) . Protein A could bind platelets via an IgG bridge to the platelet Fc receptor, or via von Willebrand factor, which binds to GPIb (Hartlieb et al., 2000) , or by interacting directly with the complement receptor gC1qR/p33 (Nguyen et al., 2000) . These potential interactions are summarized in Fig. 7 .
In summary, three S. aureus proteins have been identified that are capable of activating platelet aggregation independently. Our results indicate that ClfA is the primary factor involved because it induced aggregation with the shortest lag time when expressed on the surface of L. lactis. ClfB appears to play a secondary role, as L. lactis cells expressing ClfB activated platelet aggregation with a longer lag time compared with ClfA. L. lactis cells expressing SdrE induced platelet aggregation with a relatively long lag time, implying that this reaction is weaker Fig. 7 . Schematic representation of the known and proposed interactions between S. aureus surface proteins and platelet receptors. ClfA and ClfB can interact with their platelet receptor(s) directly or via a fibrinogen (Fg) bridge. Similarly, protein A (Spa) can interact with at least one platelet receptor directly. Spa also interacts with different platelet receptors indirectly via an IgG or vWF bridge. SdrE appears to interact with at least one unknown platelet receptor (X) via a plasma protein bridge (Y). than that of ClfA and ClfB. SdrE appears to interact with the platelet indirectly via a plasma protein bridge, as no aggregation occurs with an S. aureus clfAclfB mutant (SdrE dependent) or with L. lactis cells expressing SdrE in gel-filtered platelets (from which the plasma proteins have been removed). Our data show that, although protein A plays a role in the induction of platelet aggregation, it is not capable of inducing the process independently. The next task is to identify the platelet receptors involved in the activation event and to determine the receptor and plasma protein involved in SdrE-promoted activation.
Experimental procedures
Materials ADP and arachidonic acid were purchased from Bio-Data. Prostaglandin E 1 was from Sigma. Human monoclonal antibody c7E3 (abciximab) recognizing GPIIb (CD41) was obtained from Eli Lilly. The GPIIb/IIIa antagonist eptifibatide was a kind gift from Dr D. Philips (COR Therapeutics, San Francisco, CA, USA). Tirofiban was from Merck. Peroxidaselabelled goat anti-rabbit polyclonal IgG and fluorescein isothiocyanate (FITC)-labelled swine anti-rabbit polyclonal IgG were purchased from Dako. Enzymes for DNA manipulation were purchased from Roche, Sigma Chemical, New England Biolabs and Stratagene and were used in accordance with the manufacturers' instructions. Human fibrinogen was obtained from Calbiochem. Bacterial growth media were from Oxoid. Recombinant lysostaphin was obtained from AMBI. Other chemicals were purchased from Sigma or BDH.
Bacterial strains and growth conditions
Escherichia coli XL1-Blue (Stratagene) were used for plasmid cloning. E. coli Topp3 (Qiagen) were used for the expression of S. aureus recombinant proteins. All E. coli cells were grown in L broth (Oxoid) at 37∞C with shaking. S. aureus cells were grown in brain-heart infusion (BHI) broth (Oxoid) at 37∞C with shaking. L. lactis strain MG1363 (Gasson, 1983) was used for plasmid cloning and heterologous expression of S. aureus surface proteins. L. lactis MG1363 was routinely grown statically on M17 agar or broth (Difco), incorporating 0.5% glucose at 30∞C. The following antibiotics were incorporated into the media where appropriate: ampicillin (100 mg ml -1 ), erythromycin (5 or 10 mg ml -1 ), kanamycin (100 mg ml -1 ), chloramphenicol (10 mg ml -1 ) and tetracycline (2 mg ml -1 ).
Staphylococcus aureus (Newman) strains defective in protein A (spa::Ka r ; DU5971) (F. Roche, unpublished), clumping factor A (clfA2::Tn917; DU5876) (McDevitt et al., 1994) , clumping factor B (clfB::Tc r ; DU5943) (Ní Eidhin et al., 1998) and the double clfA::Tn917 clfB::Tc r mutant (DU5944) (Ní Eidhin et al., 1998) , coagulase (coa::Em r ; DU5856) (Phonimdaeng et al., 1990) , the fibronectin-binding proteins A and B (fnbA::Tc r fnbB::Em r ; DU5886) (Greene et al., 1995) , the elastin-binding protein (ebpS::Em r ; DU5981) (Downer et al., 2002) and capsular polysaccharide (cap5B1::Tn917; DU5912) (Wann et al., 1999) have been described previously. A mutant defective in the MHC class II analogous protein Map was a gift from B. Kreikemeyer and M. Höök (Texas A and M University, USA).
Insertion mutations in sdrC and sdrD were constructed by directed integration of the temperature-sensitive plasmid pG + Host9 (Maguin et al., 1996; Hartford et al., 2001) . A fragment internal to the region encoding the unique A domain of each protein was amplified by polymerase chain reaction (PCR; primer sequences are available on request) and cloned into the multiple cloning site of pG + Host9. The plasmid was constructed in E. coli and transferred into S. aureus Newman (Oskouian and Stewart, 1990) . Selection for growth at the restrictive temperature in the presence of erythromycin resulted in derivatives in which the plasmid had integrated into the sdrC or sdrD genes to form Newman sdrC::pG + Host9 (DU5988) and Newman sdrD::pG + Host9 (DU5989).
A similar strategy to that described above failed to generate an insertion mutation in sdrE. Thus, a deletion mutation in the closely linked sdrC, sdrD and sdrE genes of strain Newman (DsdrCDE::Tc r ) was constructed by allelic replacement and transduction in a two-step procedure. Initially, a deletion-substitution sdrC sdrD mutation was constructed by allele replacement in the chromosome of S. aureus 8325-4, a strain that lacks sdrE, forming strain DU5972. A fragment of 814 bp from within the unique A region of sdrC was amplified by PCR using primers sdrCF3 and sdrCR3, and a fragment of 916 bp from within the A region of sdrD was amplified by primers sdrDF3 and sdrDR3 (primer sequences available upon request). The primers placed a BamHI site at the 5¢ end of the sdrC amplimer and a HindIII site at the 3¢ end to facilitate cloning into a plasmid vector. A HindIII site was placed at the 5¢ end of the sdrD amplimer, whereas an EcoRI site was place at the 3¢ end. The sdrC PCR fragment was cleaved with BamHI and HindIII, and the sdrD PCR product was cleaved with HindIII and EcoRI. These products were ligated together at the HindIII site and cloned between the BamHI and EcoRI sites of pBluescript KS+ (Short et al., 1988) , which had been cut with BamHI and EcoRI. A HindIII fragment encoding the tetK gene was cloned from pT181 (Khan and Novick, 1983) into the HindIII site separating the cloned sdrC and sdrD fragments. Subsequently, plasmid pTS2, which is temperature sensitive for replication in S. aureus (Greene et al., 1995) , was cloned into the XbaI site of the chimeric plasmid, which was then transferred into S. aureus 8325-4. Allele replacement was performed by temperature shift experiments (Foster, 1998) . The structure of the DsdrCD::Tc r mutation was verified by Southern hybridization (data not shown). The mutation was transduced into S. aureus (Newman), where it replaced the wild-type sdrCDE locus forming Newman DsdrCDE::Tc r (DU5973). The mutated locus was verified by Southern hybridization (data not shown).
The DsdrCDE::Tc r mutation was transduced (Foster, 1998) into Newman spa::Ka r to construct strain DU5974 sdrCDE spa. The clfA::Tn917 mutation was then transduced into DU5974, forming DU5975 sdrCDE spa clfA, into DU5971, forming DU5976 clfA spa, and into DU5973, forming DU5995. The presence of the DsdrCDE::Tc r mutation, the Newman spa::Ka r and the clfA::Tn917 mutations in DU5975 was verified by PCR (data not shown).
Expression of S. aureus proteins by L. lactis MG1363
The clfA, clfB, sdrC, sdrD sdrE, map and spa genes were amplified by PCR and cloned into the expression vector pKS80 (Hartford et al., 2001) in L. lactis MG1363. Each primer carries a BamHI site to facilitate in frame fusion of the start codon of the S. aureus gene with the ATG codon located within the BclI site downstream from a ribosome binding site in the vector. The PCR products were cleaved with BamHI, ligated with BclI-cleaved pKS80 and electrotransformed into L. lactis MG1363 cells made competent as described previously (Wells et al., 1993) . Transformants were selected on M17 agar containing 5 mg ml -1 erythromycin and 0.5% glucose. Transformants were tested for protein expression by whole-cell dot immunoblotting (Hartford et al., 1997) using specific antibodies recognizing the A domains of each protein (McDevitt et al., 1994; Josefsson et al., 1998b; Ní Eidhin et al., 1998) , with the exception of protein A, in which nonimmune rabbit IgG was used. Bound antibodies were detected with protein A coupled to horseradish peroxidase (Sigma) and chemiluminescence. L. lactis MG1363 expressing EbpS was a kind gift from R. Downer, Trinity College, Dublin.
Recombinant SdrE A domain
The unique A domain of SdrE was expressed as a recombinant protein with a 6¥ His affinity tag at the N-terminus. The coding sequence of the A domain was amplified by PCR (primer sequences available upon request) and cloned between the BamHI-HindIII sites of the expression vector pQE30 (Qiagen). The plasmids were transformed into E. coli Topp3, and proteins were purified by Ni 2+ -chelate chromatography (O'Connell et al., 1998) . Anti-SdrE A domain antibodies were generated by immunization of a young New Zealand white rabbit (McAleese et al., 2001) . of PRP or GFPs. Platelet aggregation was assayed by light transmission at 37∞C using a PAP-4 aggregometer (BioData). Platelets were tested for normal responses to arachidonic acid (0.5 mg ml -1 ) and/or ADP (20 mM). The GFPs were adjusted to a final concentration of 2 ¥ 10 8 platelets ml -1 . Physiological concentrations of CaCl 2 (1.8 mM) and fibrinogen (1 mg ml -1 ) were added to GFPs before aggregation studies. Aspirin was preincubated with PRP for 45 min at 37∞C before the addition of agonist or S. aureus. Apyrase, PGE 1 and inhibitors of GPIIb/IIIa were incubated with PRP for 10 min at 37∞C before the addition of S. aureus or specific agonist.
Adherence to immobilized fibrinogen
Adherence of bacteria to immobilized fibrinogen was measured as described previously (Hartford et al., 1997) . Briefly, flat-bottomed microtitre plates were coated with a solution of human fibrinogen (5 mg ml -1 in PBS) and blocked with 2 mg ml -1 bovine serum albumin in PBS. Bacterial cells were grown to stationary phase and resuspended at an OD 600 of 1.0 in PBS. A sample of 100 ml of cells were added to each well and incubated at 37∞C for 2 h. Adherent cells were fixed with 25% (v/v) formaldehyde, stained with 0.5% (w/v) crystal violet and read in an enzyme-linked immunosorbent assay (ELISA) reader at 570 nm.
